Screener
Emergent Biosolutions EBS Product and services sales, net — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Emergent Biosolutions in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Emergent Biosolutions’s 10-Q, filed August 6, 2026.
- Filed
- Aug 5, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001367644-26-000082
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Revenues: | ||||
| Product and services sales, net | $226.8 | $130.3 | $376.5 | $339.4 |
| Contracts and grants | 7.5 | 10.6 | 13.9 | 23.7 |
| Total revenues | 234.3 | 140.9 | 390.4 | 363.1 |
| Operating expenses: | ||||
| Cost of product and services sales, net (1) | 97.1 | 66.9 | 169.1 | 155.4 |
| Research and development | 9.2 | 12.5 | 19.7 | 27.6 |
| Selling, general and administrative | 44.6 | 43.7 | 91.2 | 96.1 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Emergent Biosolutions's product and services sales, net — total revenues?
- Emergent Biosolutions (EBS) reported product and services sales, net — total revenues of $226.8M in Q2 2026.
- How has Emergent Biosolutions's product and services sales, net — total revenues changed year-over-year?
- Emergent Biosolutions's product and services sales, net — total revenues increased by 74.1% year-over-year, from $130.3M to $226.8M.
- What is the long-term trend for Emergent Biosolutions's product and services sales, net — total revenues?
- Over 2 years (2023 to 2025), Emergent Biosolutions's product and services sales, net — total revenues has grown at a -17.0% compound annual growth rate (CAGR), from $1.02B to $705.2M.
- What does product and services sales, net — total revenues mean?
- This metric represents the total net revenue generated specifically from the company's product and service offerings, excluding other revenue streams. It serves as a primary indicator of the commercial performance and market adoption of the firm's core portfolio. Monitoring this figure helps investors assess the underlying demand for the company's specialized health solutions and the effectiveness of its commercialization strategy.
Ask your AI about Emergent Biosolutions's product and services sales, net — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude